Verici Dx plc (VRCI.L)

7.25 0.00 (0.00%) At close: 03:58PM BST

Verici Dx plc

Avon House
19 Stanwell Road Cardiff
Penarth CF64 2EZ
United Kingdom
44 20 7933 8780
https://www.vericidx.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 14

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Sara Barrington A.C.A., A.C.I.M.	CEO & Executive Director	285.59k	N/A	1967
Mr. David M. Anderson	Chief Financial Officer	N/A	N/A	1963
Mr. Salim Gulamabbas Hamir F.C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.

Corporate governance

Verici Dx plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.